Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
28 03 2019
28 03 2019
Historique:
received:
11
10
2018
accepted:
21
12
2018
pubmed:
12
1
2019
medline:
4
12
2019
entrez:
12
1
2019
Statut:
ppublish
Résumé
The prevention of relapse is the major therapeutic challenge in older patients with acute myeloid leukemia (AML) who have obtained a complete remission (CR) on intensive chemotherapy. In this randomized phase 3 study (HOVON97) in older patients (≥60 years) with AML or myelodysplastic syndrome with refractory anemia with excess of blasts, in CR/CR with incomplete hematologic recovery (CRi) after at least 2 cycles of intensive chemotherapy, we assessed the value of azacitidine as postremission therapy with respect to disease-free survival (DFS; primary end point) and overall survival (OS; secondary end point). In total, 116 eligible patients were randomly (1:1) assigned to either observation (N = 60) or azacitidine maintenance (N = 56; 50 mg/m
Identifiants
pubmed: 30630862
pii: S0006-4971(20)42668-0
doi: 10.1182/blood-2018-10-879866
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Azacitidine
M801H13NRU
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1457-1464Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.